Literature DB >> 461145

[Measurements of serum C3d in primitive chronic glomerular nephropathies (author's transl)].

G Lagrue, A Branellec, L Intrator, M Moisy, A Sobel.   

Abstract

Measurement of serum C3 does not provide precise informations concerning an eventual consumption of this complement component during an immunological process. An increased synthetic rate may compensate an accelerated catabolism. The study of breakdown products of C3, such as C3d is a more sensitive approach of the role of complement in some immunological disorders. Therefore C3d was measured in the serum of patients with chronic non systemic glomerular diseases. High values of serum C3d were found in all cases of hypocomplementemic glomerulonephritis. Circulating C3d was also increased to a lower extent, in patients with normocomplementemic nephritis such as minimal change disease, mesangial nephritis with IgA deposits and membraneoproliferative (type I) glomerulonephritis. The data suggested the involvement of complement in a number of glomerulonephritis. Participation of complement in immunological disorders particularly in chronic non systemic glomerulonephritis could require a reevaluation when functional tests are performed in addition to static measurements.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 461145

Source DB:  PubMed          Journal:  Nouv Presse Med        ISSN: 0301-1518


  5 in total

Review 1.  Biomarkers in IgA nephropathy: relationship to pathogenetic hits.

Authors:  Margaret Colleen Hastings; Zina Moldoveanu; Hitoshi Suzuki; Francois Berthoux; Bruce A Julian; John T Sanders; Matthew B Renfrow; Jan Novak; Robert J Wyatt
Journal:  Expert Opin Med Diagn       Date:  2013-11

Review 2.  Current Understanding of the Role of Complement in IgA Nephropathy.

Authors:  Nicolas Maillard; Robert J Wyatt; Bruce A Julian; Krzysztof Kiryluk; Ali Gharavi; Veronique Fremeaux-Bacchi; Jan Novak
Journal:  J Am Soc Nephrol       Date:  2015-02-18       Impact factor: 10.121

3.  The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  W J Morrow; D J Williams; C Ferec; R Casburn-Budd; D A Isenberg; E Paice; M L Snaith; P Youinou; P Le Goff
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

4.  Inhibition of neutrophil migration by serum IgA from patients with IgA nephropathy.

Authors:  J Egido; J Sancho; F Lorente; G Fontan
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

Review 5.  The Origin and Activities of IgA1-Containing Immune Complexes in IgA Nephropathy.

Authors:  Barbora Knoppova; Colin Reily; Nicolas Maillard; Dana V Rizk; Zina Moldoveanu; Jiri Mestecky; Milan Raska; Matthew B Renfrow; Bruce A Julian; Jan Novak
Journal:  Front Immunol       Date:  2016-04-12       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.